Targeted drug combo shows promise against melanoma
By REUTERS
CHICAGO - The combination of two experimental pills developed by GlaxoSmithKline Plc has shown promise as a treatment for melanoma, the most deadly type of skin cancer, according to new research.The early stage trial involved patients with advanced melanoma with a specific genetic mutation who were treated with drugs designed to block MEK (GSK212) and BRAF (GSK436), two components of the same pathway used by the cancer to drive tumor growth.Netanyahu: With, without agreement Hezbollah must be north of Litani